- Previous Close
594.00 - Open
598.00 - Bid 586.00 x --
- Ask 596.00 x --
- Day's Range
586.00 - 610.00 - 52 Week Range
481.00 - 660.00 - Volume
107 - Avg. Volume
59 - Market Cap (intraday)
18.356B - Beta (5Y Monthly) 0.52
- PE Ratio (TTM)
11.89 - EPS (TTM)
49.96 - Earnings Date Mar 12, 2025 - Mar 17, 2025
- Forward Dividend & Yield 32.21 (4.99%)
- Ex-Dividend Date Jul 23, 2024
- 1y Target Est
--
Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. Its prescription pharmaceuticals include medicines for the treatment of cardiovascular, alimentary tract and metabolism, central nervous system, infections, oncology, and other diseases. The company also provides non-prescription products for oral cavity and pharynx; cough and cold; analgesics; nasal products; vitamin and mineral products; products for enhancing cerebral and peripheral circulation; products for enhancing digestive tract and digestion; health care products; and others. In addition, it offers animal health products comprising analgesics antimicrobials, antiparasitics, disinfectants, vitamins, and minerals. Further, the company provides health resort and tourist services. Krka, d. d. was founded in 1954 and is headquartered in Novo Mesto, Slovenia.
www.krka.si12,675
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: KRK.WA
View MorePerformance Overview: KRK.WA
Trailing total returns as of 1/6/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRK.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRK.WA
View MoreValuation Measures
Market Cap
18.36B
Enterprise Value
15.98B
Trailing P/E
11.89
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.25
Price/Book (mrq)
1.95
Enterprise Value/Revenue
1.96
Enterprise Value/EBITDA
7.26
Financial Highlights
Profitability and Income Statement
Profit Margin
17.65%
Return on Assets (ttm)
8.71%
Return on Equity (ttm)
14.43%
Revenue (ttm)
1.83B
Net Income Avi to Common (ttm)
323.81M
Diluted EPS (ttm)
49.96
Balance Sheet and Cash Flow
Total Cash (mrq)
563.62M
Total Debt/Equity (mrq)
0.56%
Levered Free Cash Flow (ttm)
16.76M